Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review
About this episode
Dr. McKay discusses androgen pathway-targeting agents and clinical findings from the ESMO Congress 2025.
Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here .
More episodes of Prostate Cancer Update
- Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
- Metastatic Bladder Cancer — Rapid Case Review Issue 4
- AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
- Metastatic Bladder Cancer — Rapid Case Review Issue 3
- Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
- Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review
Explore listener stats, chart rankings, contacts and more on the Prostate Cancer Update podcast page.